Table 1 Characteristics of the study population prior to receiving the first monoclonal antibody
Characteristic | Total (n = 171) |
|---|---|
Female, n (%) | 143 (83.6) |
Age in years, mean (SD) | 43.16 ± 12.54 |
Diagnosis | |
Episodic Migraine, n (%) | 85 (49.7) |
Chronic Migraine, n (%) | 86 (50.3) |
Aura, n (%) | 55 (32.2) |
1st MAb | |
Erenumab, n (%) | 89 (52.0) |
Galcanezumab, n (%) | 39 (22.8) |
Fremanezumab, n (%) | 43 (25.1) |
Withdrawal, n (%) | 26 (15.2) |
MRM, n (%) | 33 (19.3) |
MOH, n (%) | 62 (36.3) |
Other headache disorders, n (%) | 44 (25.7) |
Number of prophylactic medications, median [IQR] | 2.00 [2] |
Non-daily migraine headache in CM, n (%) | 67 (77.9) |
Mean migraine days/month (EM), median | 10.00 [4] |
Mean migraine days/month (CM), median | 20.00 [11] |
Age at Migraine Diagnosis, median [IQR] | 15.00 [13] |
Disease duration, median [IQR] | 21.00 [21] |
Psychiatric comorbidity, n (%) | 59 (34.5) |